Issued: Dec-21-2012

SAFETY DATA SHEET

Section 1. Identification of the substance/mixture and of the company/undertaking

1.1 Product Identifier

Product Name: Terazosin Monohydrochloride Dihydrate

Chemical Name: 1-(4-Amino-6-7-dimethoxy-2-quinazolinyl)4-(2-

tetrahydrofuranylcarbonyl)piperazine Hydrochloride Dihydrate

Synonyms: Terazosin Hydrochloride Dihydrate: Terazosin: Terazosin Hydrochloride

Drug Code Number: 81831: 44735: 66398

1.2 Relevant identified uses of the substance or mixture and uses advised against

Recommended use: Pharmaceuticals

1.3 Details of the supplier of the safety data sheet

Supplier: AbbVie Inc.

North Chicago, IL 60064

U.S.A.

1-800-255-5162 +1-847-937-7433

Manufacturer European: AbbVie Ireland Pharmaceutical Operations

Manorhamilton Road

Sligo IRELAND

Customer Service Telephone: 1-800-255-5162 (US and Canada only)

+1-847-937-7433

E-mail Address: AbbVie.SDS@abbvie.com

1.4 Emergency telephone number

Emergency Telephone: CHEMTREC: 1(800) 424-9300 (in USA and Canada)

or +1-703-527-3887 (international)

Section 2. Hazards identification

2.1 Classification of the substance or mixture

Regulation (EC) No 1272/2008

Skin corrosion/irritationCategory 2Serious eye damage/eye irritationCategory 2Reproductive toxicityCategory 2Specific target organ systemicCategory 3

toxicity (single exposure)

None

Issued: Dec-21-2012

Section 2. Hazards identification

Classification according to EU Directives 67/548/EEC or 1999/45/EC

Indication of danger: Xi - Irritant

Risk Phrases: R36 - Irritating to eyes

R37 - Irritating to respiratory system

R38 - Irritating to skin

R62 - Possible risk of impaired fertility

2.2 Label elements



Signal Word: Warning

Hazard Statements: H315 - Causes skin irritation

H319 - Causes serious eye irritation H335 - May cause respiratory irritation

H361 - Suspected of damaging fertility or the unborn child

P302 + P352 - IF ON SKIN: Wash with plenty of soap and water

P280 - Wear protective gloves/protective clothing/eye protection/face protection P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes.

Remove contact lenses, if present and easy to do. Continue rinsing

P304 + P340 - IF INHALED: Remove to fresh air and keep at rest in a position

comfortable for breathing

P312 - Call a POISON CENTER or doctor/physician if you feel unwell

P403 + P233 - Store in a well-ventilated place. Keep container tightly closed

2.3 Other hazards

Not determined

Section 3. Composition/information on ingredients

Chemical Name	Percent	EINECS/ELINCS Number	EEC Classification	EU - GHS Substance Classification	REACH No.
Terazosin Hydrochloride	98-100	NA	Xi; R36/37/38, R62	` /	No data available
70024-40-7				Skin Irrit. 2 (H315)	
				Eye Irrit. 2 (H319)	
				Repro 2 (H361)	

Not Hazardous* - Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

For the full text of the R-phrases mentioned in this Section, see Section 16

Issued: Dec-21-2012

For the full text of the H-Statements mentioned in this Section, see Section 16

Section 4. First aid measures

4.1 Description of first aid measures

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation

persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation

persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention.

Provide symptomatic/supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention.

Provide symptomatic/supportive care as necessary.

Protection of First-aiders: Use personal protective equipment

4.2 Most important symptoms and effects, both acute and delayed

Signs and Symptoms: Clinical data suggests the following: headaches, lightheadedness, nausea, dizziness,

fatigue, ringing in the ear, fast heart rate, palpitation, nasal congestion, decreased blood pressure. These clinical signs are generally of short duration and mild. Clinical

overdose may result in the following: vomiting, abdominal pain, diarrhea.

Medical Conditions None known from occupational exposure. Data suggest any pre-existing ailments in

Aggravated by Exposure: the following organs: cardiovascular system.

4.3 Indication of any immediate medical attention and special treatment needed

Notes To Physician: Treat symptomatically

Additional Information: These effects are of short duration.

Section 5. Firefighting measures

5.1 Extinguishing Media

Suitable Extinguishing Media: Use extinguishing agent suitable for type of surrounding fire

Unsuitable Extinguishing Media: Not determined

5.2 Special hazards arising from the substance or mixture

Special Exposure Hazards: This material is capable of forming explosive dust clouds in air, therefore, measures

must be taken to avoid ignition. This material is particularly sensitive to ignition by

electrostatic discharge.

5.3 Advice for firefighters

Protective Equipment and Precautions for Firefighters:

As in any fire, wear self-contained breathing apparatus and full protective gear

Issued: Dec-21-2012

Section 6. Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal Precautions: For personal protection see section 8

6.2. Environmental precautions

Environmental Precautions: Contain material and prevent release to waterways or soil.

6.3. Methods and material for containment and cleaning up

Methods for Cleaning Up: Recover product and place in an appropriate container for disposal.

Incompatibilities: Oxidizers.

6.4. Reference to other sections

Refer to Sections 8, 12, and 13 for further information.

Section 7. Handling and storage

7.1. Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Store according to label instructions

7.3. Specific end use(s)

Recommended use: Pharmaceuticals

Section 8. Exposure controls/personal protection

8.1. Control parameters

Exposure limits:

Chemical Name Employee Exposure Limit		Skin Notation
Terazosin Hydrochloride	10 mcg/m ³ in 8-hour TWA	None
70024-40-7	-	

8.2. Exposure controls

Engineering Controls: Use inside a hood, glovebox or process enclosure.

Respiratory Protection: An approved respirator (i.e. NIOSH, EN, etc.) should be worn when exposures are

expected to exceed the applicable limits.

Eyes: Wear eye protection appropriate to handling activities.

Gloves: Impervious gloves.

Issued: Dec-21-2012

Other PPE Data: Wear appropriate body coverings if contact may occur.

Environmental Exposure

Controls:

Not determined

Section 9. Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance: White to light yellow Crystalline Powder

Odor: Odorless.
Odor Threshold: Not determined
pH: 4.0 as a 1% solution.
Boiling Pt. @ 760 mm Hg (°C): Not determined.

Melting/Freezing Point (°C): 271-274

Flash Point (°C): Not determined. **Evaporation Rate at 20°C:** Not determined. Flammability (Solid): Not determined. **Lower Explosive Limit:** Not determined. **Upper Explosive Limit:** Not determined. Vapor Pressure (mm Hg): Not determined. Vapor Density (Air = 1): Not determined. **Specific Gravity:** Not determined.

Soluble in: water, methanol.

Partition coefficient: n- Not determined.

octanol/water

Autoignition Temp. (°C): 500-520

Decomposition temperature (°C): Not determined. **Viscosity (centipoise):** Not determined. **Explosion Severity:** Not determined. **Oxidizer Properties:** Not determined.

9.2. Other information

Maximum Pressure Rise (bar): 8.6 Max. rate of pressure rise 645

(bar/sec):

Kst Value (bar.m/s): 175 **Min. Ignition Energy-Cloud** 50-100

(m.I):

Min. Explosive Conc. (g/m^3) : < 100

Section 10. Stability and reactivity

10.1. Reactivity

Not determined

10.2. Chemical stability

Stable under normal conditions

Issued: Dec-21-2012

10.3. Possibility of hazardous reactions

Hazardous reactions: Not determined.

Self-Heating Tendency: No exotherms seen below 200 deg C in DSC testing.

10.4. Conditions to avoid

Not determined.

10.5 Incompatible materials

Oxidizing agents

10.6 Hazardous decompostion products

Carbon oxides, Nitrogen oxides (NOx), Hydrogen chloride

Section 11. Toxicological information

11.1. Information on toxicological effects

Routes of Exposure:

Oral: Yes
Dermal: Yes
Inhalation: Yes

Acute Toxicity - Oral: Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Terazosin Hydrochloride	LD50 =	2700-10,000	mg/kg	Mice Rats
70024-40-7		·		

Acute Toxicity - Dermal: Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Terazosin Hydrochloride	LD50 >	2000	mg/kg	Rabbits
70024-40-7				

Acute Toxicity - Inhalation: Not determined.

Corrosivity: Not determined.

Dermal Irritation: May be a skin irritant.

Eye Irritation: Produced mild to moderate eye irritation in rabbits. Recovery after 48 hours.

Sensitization: Negative in the maximization assay in guinea pigs at challenge concentrations.

Toxicokinetics/Metabolism: Not determined.

Target Organ Effects: May cause respiratory tract irritation

Reproductive Effects: In animals adverse reproductive effects include: testicular atrophy.

Data for component (s) given below.

Chemical Name	Species	Dosage	Units	Route	Duration
Terazosin Hydrochloride	Rats	40	mg/kg	Not specified	Not specified
70024-40-7				•	•

Issued: Dec-21-2012

Carcinogenicity: Not determined.

Mutagenicity: Data for component (s) given below.

Chemical Name	Micronucleus Assay	Ames Test:	Mouse Lymphoma Assay	Chromosomal Abbr. Assay
Terazosin Hydrochloride 70024-40-7	Negative	Negative	No Data.	Negative

Aspiration hazard: Not determined

Notes:

1. ALD: Approximate lethal dosage

2. LC50: Concentration in air that produces 50% mortality

3. LD50: Oral or dermal dosage that produces 50% mortality

Section 12. Ecological information

12.1. Toxicity

Not determined.

12.2. Persistence and degradability

Not determined.

12.3. Bioaccumulative potential

Not determined

12.4. Mobility in soil

Not determined.

12.5. Results of PBT or vPvB assessment

Chemical safety report is not required for this substance/product.

12.6. Other adverse effects

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

Notes:

- 1. EC50: Concentration in water that produces 50% mortality in Daphnia sp.
- 2. LC50: Concentration in water that produces 50% mortality in fish.
- 3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.

Section 13. Disposal considerations

13.1 Waste treatment methods

Waste Disposal Methods: Disposal should be made in accordance with country, federal, state and local

regulations.

Issued: Dec-21-2012

Section 14. Transport information

ADR, DOT, ICAO/IATA, IMDG/IMO

Status: Not regulated

14.1. UN Number: Not applicable
14.2. Proper shipping name: Not applicable
14.3. Hazard class: Not applicable
14.4. Packing group: Not applicable
14.5. Environmental hazard: Not applicable
14.6. Special Provisions: Not applicable
14.7. Transport in bulk according Not applicable

to Annex II of MARPOL 73/78

and the IBC Code:

Section 15. Regulatory Information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Terazosin Hydrochloride	-	-	-	Not listed.	-
70024-40-7					

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Terazosin Hydrochloride	-	-	-	-	-	
70024-40-7						

Legend

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

PICCS - Philippines Inventory of Chemicals and Chemical Substances

ENCS - Japan Existing and New Chemical Substances

ISHL - Japan Industrial Safety and Health Law

IECSC - China Inventory of Existing Chemical Substances

AICS - Australian Inventory of Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

Carcinogenicity Rating:

Chemical Name	Percent	NTP:	IARC:	ACGIH:
Terazosin Hydrochloride	98-100	Not Listed	Not Listed	Not Listed

SARA 313 Information

Chemical Name	Percent	SARA 313 Chemical:	CERCLA RQ/SARA	SARA EHS TPQ (lbs):
			EHS RQ (lbs):	
Terazosin Hydrochloride	98-100	No	Not Applicable	Not applicable

Immediate Health:YesDelayed Health:NoFire:No

Issued: Dec-21-2012

Sudden Pressure: No Reactivity: No

RCRA Status: Not determined.

Proposition 65 Status: Does not contain chemicals known to the state of California to cause cancer or

reproductive harm.

WHMIS Hazard Class: Not determined.

NFPA Rating:

Health: 1 Fire: 1

Reactivity: 0

Notes:

1. SARA = Superfund Amendments and the Reauthorization Act.

2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.

3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.

4. TSCA = Toxic Substances Control Act.

5. EC = European Community.

6. WHMIS = Canadian Workplace Hazardous Materials Information System.

7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

15.2. Chemical safety assessment

Chemical safety assessment has not been conducted on the substance/product.

Section 16. Other information

Risk Phrases: R36 - Irritating to eyes, R37 - Irritating to respiratory system, R38 - Irritating to skin,

R62 - Possible risk of impaired fertility

Full text of H-Statements referred to under sections 2 and 3

H335 - May cause respiratory irritation, H315 - Causes skin irritation, H319 - Causes serious eye irritation

Document Authored By: Global Occupational Toxicology (D-03QC)

Issued: Dec-21-2012

Supersedes the SDS dated: Dec-13-2010

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, AbbVie Inc. does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. AbbVie Inc. assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.